For the quarter ended September 2024, Elevance Health (ELV) reported revenue of $44.72 billion, up 5.3% over the same period last year. EPS came in at $8.37, compared to $8.99 in the year-ago quarter. The reported revenue compares to the Zacks Consensus Estimate of $43.26 billion, representing a surprise of +3.37%. The company delivered an EPS surprise of -13.71%, with the consensus EPS estimate being $9.70. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- ...

On Thursday, Elevance Health Inc. ELV reported third-quarter revenues of $44.7 billion, up 5.3% year-overyear, beating the consensus of $43.33 billion. The increase was driven by higher premium yields in the Health Benefits segment and growth in CarelonRx product revenue, partially offset by membership attrition in the Medicaid business. The benefit expense ratio was 89.5%, an increase of 270 basis points, driven primarily by the timing mismatch between Medicaid rates and the higher acuity of members. "We r ...

Elevance Health (ELV) came out with quarterly earnings of $8.37 per share, missing the Zacks Consensus Estimate of $9.70 per share. This compares to earnings of $8.99 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -13.71%. A quarter ago, it was expected that this health insurer would post earnings of $9.99 per share when it actually produced earnings of $10.12, delivering a surprise of 1.30%. Over the last four quarters, the ...

E A R N I N G S R E L E A S E ELEVANCE HEALTH REPORTS THIRD QUARTER 2024 RESULTS • 3Q 2024 operating revenue of $44.7 billion 1 • 3Q 2024 adjusted operating gain of $2.4 billion 2 1 • 3Q 2024 diluted EPS of $4.36; adjusted diluted EPS of $8.37 • 4Q 2024 dividend of $1.63 per share declared to shareholders Indianapolis, IN - October 17, 2024 - Elevance Health, Inc. (NYSE: ELV) reported third quarter 2024 results. "We remain confident in the long-term earnings potential of our diverse businesses as we navigat ...

Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering Elevance Health (ELV) , which belongs to the Zacks Medical Services industry. This health insurer has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports. The average surprise for the last two quarters was 1.13%. For the last reported quarter, Elevance Health came out with earnings of $10.12 per share versus t ...

Elevance Health, Inc. (ELV) is set to report its third-quarter 2024 results on Oct. 17, 2024, before the opening bell. The Zacks Consensus Estimate for the to-be-reported quarter's earnings and revenues is pegged at $9.74 per share and $43.2 billion, respectively. Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar. The earnings estimate for the to-be-reported quarter has witnessed downward revisions over the past 60 days. The bottom-line projection indicates year-over-year growth of 8. ...

In its upcoming report, Elevance Health (ELV) is predicted by Wall Street analysts to post quarterly earnings of $9.74 per share, reflecting an increase of 8.3% compared to the same period last year. Revenues are forecasted to be $43.23 billion, representing a year-over-year increase of 1.8%. The current level reflects no revision in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections ...

Thanks for reading! We look for high quality stocks trading at attractive valuations in our Marketplace service entitled Cash Flow Compounders: The Best Stocks in the World. Our focus is high return on equity, high free cash flow stocks with a proven track record in compounding earnings at higher than market rates. There we provide in depth research, with 2-4 new, high quality ideas per month. Our ideas have earned returns well above benchmark levels over many years. Sign up for a free 2 week trial to get m ...

Elevance Health, Inc. (ELV) is well-poised to grow on the back of Carelon's business strength and commercial member growth. The company keeps expanding its operating margins for both Health Benefits and Carelon units, which positions it for improving profits. Elevance Health — with a market cap of $114.2 billion — is a major health benefits company. Courtesy of solid prospects, this Zacks Rank #2 (Buy) stock is worth adding to your portfolio at the moment. Let's delve deeper. ELV's One-Year Price Performanc ...

Elevance Health, Inc. (ELV) is well-poised to grow on the back of Carelon's business strength and commercial member growth. The company keeps expanding its operating margins for both Health Benefits and Carelon units, which positions it for improving profits. Elevance Health — with a market cap of $129.1 billion — is a major health benefits company. Courtesy of solid prospects, this presently Zacks Rank #3 (Hold) stock is worth retaining at the moment. Let's delve deeper. ELV YTD Price Performance Shares of ...